Novel strategies to overcome barriers to commercialisation of new technologies: a case study from the Australian biotechnology industry Online publication date: Fri, 13-Jan-2006
by Damian Hine, Damien W. Millen
International Journal of Technology Transfer and Commercialisation (IJTTC), Vol. 5, No. 1/2, 2006
Abstract: The biotechnology industry is shifting its value creation emphasis from R&D to manufacturing and market. Business models need to keep pace with this evolution. This paper reports on a single-case study of a new biotechnology firm, EpiTan Limited, and the life cycle stages it has progressed through in parallel with the Australian biotechnology industry. EpiTan offers an alternative business model to that typical of New Biotechnology Firms (NBFs), which sets the agenda for fast-tracking the development of biotechnology companies through effective product selection and market targeting. It has managed to overcome the initial obstacles that typically hinder the growth and competitiveness of an NBF, by being founded around a robust IP portfolio and a board and management team with high level international expertise. EpiTan has built strong international networks and strategic alliances to gain efficiencies and maximise its global competitiveness.
Online publication date: Fri, 13-Jan-2006
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Technology Transfer and Commercialisation (IJTTC):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email firstname.lastname@example.org